← 返回

TRIM3/TLR3 轴克服 IFN-β反馈抑制以抑制 NSCLC 进展

英文原题:The TRIM3/TLR3 axis overrides IFN-β feedback inhibition to suppress NSCLC progression.

查看英文原题

The TRIM3/TLR3 axis overrides IFN-β feedback inhibition to suppress NSCLC progression.

PubMed 2026/01/16(内容时间) Cell Death Dis Q1 · IF 12.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

干扰素-β(IFN-β)具有强效抗肿瘤活性,但其临床治疗潜力受到抑制IFN-β产生的内在负反馈环路的削弱。然而,非小细胞肺癌(NSCLC)中调控IFN-β稳态的反馈机制仍不清楚。

我们发现,三重基序包含蛋白3(TRIM3)促进IFNB1的转录和mRNA表达。相反,过量的IFN-β抑制TRIM3的表达,形成二者之间的相互反馈环路。质谱分析显示,toll样受体3(TLR3)——触发IFN-β产生的关键感受器——是TRIM3的相互作用伙伴。在阐明TRIM3与TLR3之间的相互作用模式后,我们发现TRIM3/TLR3轴的激活诱导IFN-β分泌并克服了反馈抑制。持续的IFN-β分泌随后抑制NSCLC细胞增殖,并通过增加CD4+ T细胞、M1巨噬细胞和NK细胞的浸润水平重塑肿瘤微环境。

我们的发现揭示了IFN-β信号调控中的相互负反馈环路,突出了TRIM3/TLR3轴在抑制NSCLC进展中的作用,并为抑制NSCLC肿瘤生长和增强免疫治疗疗效提供了一种有前景的策略。

展开英文摘要原文

Interferon-beta (IFN-β) has potent antitumor activity, but its clinical therapeutic potential is undermined by intrinsic negative feedback loops that suppress IFN-β production.

However, the feedback mechanisms regulating IFN-β homeostasis in non-small cell lung cancer (NSCLC) remain unclear.

We found that tripartite motif containing 3 (TRIM3) promotes the transcription and mRNA expression of IFNB1. Conversely, excessive IFN-β inhibits expression of TRIM3, creating their reciprocal feedback loop. Mass spectrometry revealed that toll-like receptor 3 (TLR3), a key sensor that triggers IFN-β production, is the interacting partner of TRIM3.

Following the elucidation of the interactive mode between TRIM3 and TLR3, we found that activation of the TRIM3/TLR3 axis induced IFN-β secretion and overrode the feedback inhibition. Sustained IFN-β secretion subsequently inhibits NSCLC cell proliferation and reprograms the tumor microenvironment by increasing the infiltration levels of CD4 + T cells, M1 macrophages and NK cells.

Our findings revealed a reciprocal negative feedback loop in the regulation of IFN-β signaling, highlighting the role of the TRIM3/TLR3 axis in the suppression of NSCLC progression and offering a promising strategy to suppress tumor growth and enhance immunotherapy efficacy in NSCLC.

论文信息

作者
Xu J、Hu Q、Zhu Y、Liu Q、Wang F、Yu Y、Wang W、Ding X
第一作者单位
Department of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China.China
通讯作者单位
Department of Pharmacy, Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, China. aladdine@163.com.China
期刊
Cell death & disease2026 Jan 16
原文标识
PubMed 41545343 · DOI 10.1038/s41419-025-08265-w